Equillium (NASDAQ:EQ) Releases Earnings Results, Misses Estimates By $0.02 EPS

13 May 2026, 17:58 by Scott Moore · The Cerbat Gem

Equillium (NASDAQ:EQ – Get Free Report) announced its earnings results on Wednesday. The company reported ($0.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.02), FiscalAI reports.

Equillium Stock Performance

EQ stock traded up $0.04 during midday trading on Wednesday, reaching $2.31. 322,431 shares of the company’s stock traded hands, compared to its average volume of 466,737. The company has a 50-day moving average price of $2.02 and a two-hundred day moving average price of $1.55. Equillium has a 52 week low of $0.27 and a 52 week high of $2.70. The firm has a market capitalization of $146.06 million, a PE ratio of -4.62 and a beta of 1.67.

Insider Transactions at Equillium

In other Equillium news, COO Christine Zedelmayer sold 120,312 shares of the business’s stock in a transaction on Friday, March 13th. The shares were sold at an average price of $2.50, for a total transaction of $300,780.00. Following the sale, the chief operating officer owned 62,586 shares of the company’s stock, valued at $156,465. The trade was a 65.78% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Over the last quarter, insiders have sold 487,468 shares of company stock worth $990,467. Insiders own 17.84% of the company’s stock.

Institutional Investors Weigh In On Equillium

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Janus Henderson Group PLC bought a new stake in Equillium during the 4th quarter valued at $9,057,000. ADAR1 Capital Management LLC raised its holdings in Equillium by 0.9% during the 4th quarter. ADAR1 Capital Management LLC now owns 5,608,078 shares of the company’s stock valued at $8,693,000 after acquiring an additional 48,090 shares during the period. Woodline Partners LP bought a new stake in Equillium during the 3rd quarter valued at $5,018,000. Balyasny Asset Management L.P. raised its holdings in Equillium by 3.6% during the 4th quarter. Balyasny Asset Management L.P. now owns 2,076,250 shares of the company’s stock valued at $3,218,000 after acquiring an additional 72,602 shares during the period. Finally, Vanguard Group Inc. raised its holdings in Equillium by 59.4% during the 3rd quarter. Vanguard Group Inc. now owns 1,313,946 shares of the company’s stock valued at $1,879,000 after acquiring an additional 489,855 shares during the period. Institutional investors own 27.05% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on EQ. Stifel Nicolaus began coverage on Equillium in a research note on Wednesday, February 25th. They issued a “buy” rating and a $5.00 price objective on the stock. B. Riley Financial began coverage on Equillium in a research note on Thursday, April 16th. They issued a “buy” rating and a $6.00 price objective on the stock. Raymond James Financial began coverage on Equillium in a research note on Monday, April 13th. They issued a “strong-buy” rating and a $6.00 price objective on the stock. Wall Street Zen upgraded Equillium from a “sell” rating to a “hold” rating in a research note on Saturday, March 14th. Finally, Oppenheimer began coverage on Equillium in a research note on Thursday, April 23rd. They issued an “outperform” rating and a $7.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $7.67.

Check Out Our Latest Stock Report on Equillium

About Equillium

(Get Free Report)

Equillium, Inc (NASDAQ: EQ) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat severe autoimmune diseases and prevent organ transplant rejection. The company’s lead therapeutic candidate, EQ001 (itolizumab), is a humanized monoclonal antibody that modulates T-cell activation by targeting the CD6 receptor. Equillium’s pipeline also includes additional biologic candidates aimed at addressing indications such as acute graft-versus-host disease (GVHD) and lupus nephritis.